Search results for "Heart failure"


 
Results 81 - 90 of about 462 for "Heart failure".
Sort by: Relevance | Newest | Oldest

Early beta-blocker use may reduce 30-day mortality in patients with acute MI

Patients receiving early beta-blockers had a 30-day mortality rate of 2.3%, compared with 8.6% in those who did not, the study found.
https://immattersacp.org/weekly/archives/2016/09/27/4.htm
27 Sep 2016

Diagnosis at 10 paces for bitemporal wasting

In a new series, Pearls from I.M. Peers, Paul Dallas, MD, MACP, explains how making a simple observation in a patient could indicate a serious diagnosis.
https://immattersacp.org/archives/2022/01/diagnosis-at-10-paces-for-bitemporal-wasting.htm
1 Jan 2022

Digoxin may be linked to increased mortality risk

Digoxin may be associated with increased mortality risk, especially in patients with atrial fibrillation, according to a systematic review and meta-analysis.
https://immattersacp.org/weekly/archives/2015/05/12/5.htm
12 May 2015

AHA evaluates heart failure risks from prescription drugs, OTCs, alternative products

The scientific statement identifies prescription medications that may exacerbate underlying myocardial dysfunction, prescription drugs known to cause direct myocardial toxicity, and the sodium level of some over-the-counter medications, among other concerns.
https://immattersacp.org/weekly/archives/2016/07/19/5.htm
19 Jul 2016

How to handle uncertainty

Studies have yet to tease out how physicians' tolerance of uncertainty affects their behavior and decision making, and even their sense of burnout.
https://immattersacp.org/archives/2023/02/how-to-handle-uncertainty.htm
1 Feb 2023

Guideline updated to include new drugs for stage C heart failure with reduced ejection fraction

Among other recommendations, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or an angiotensin receptor-neprilysin inhibitor, along with a beta-blocker and an aldosterone antagonist, is the new recommended therapy to reduce morbidity and mortality in patients with chronic symptomatic heart failure with reduced ejection fraction.
https://immattersacp.org/weekly/archives/2016/05/24/2.htm
24 May 2016

A living guideline for depression treatment

ACP recommends choosing between a second-generation antidepressant or cognitive behavioral therapy for adults in the acute phase of moderate to severe major depressive disorder.
https://immattersacp.org/archives/2023/06/a-living-guideline-for-depression-treatment.htm
1 Jun 2023

Beta-blockers not associated with lower risk of death after acute MI in patients without heart failure, study finds

The insignificant effect of beta-blockers on survival was also apparent at one month and six months after discharge, as well as in separate analyses of patients with STEMI and NSTEMI.
https://immattersacp.org/weekly/archives/2017/06/06/5.htm
6 Jun 2017

Ischemic heart disease linked to worse prognosis in heart failure patients with type 2 diabetes

Type 2 diabetes was associated with greater risk for all-cause mortality in patients with ischemic and nonischemic heart failure, previous revascularization was associated with better survival, and most patients with type 2 diabetes and nonischemic heart failure had at least 1 treatable comorbid condition associated with heart failure risk.
https://immattersacp.org/weekly/archives/2016/09/20/4.htm
20 Sep 2016

Sacubitril-valsartan appears cost-effective in certain heart failure patients

Treatment value was highest in patients with class II heart failure, who also benefited most from treatment in the PARADIGM-HF trial, and improved outcomes with the drug would need to be sustained for at least 36 months to keep the cost per quality-adjusted life-year below a $100,000 threshold.
https://immattersacp.org/weekly/archives/2016/08/30/2.htm
30 Aug 2016

Result Page: Prev   4   5   6   7   8   9   10   11   12   13   Next